Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 3 6Phase 1/2 4Phase 1 4Phase NA 3Phase 4 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 276Neoplasms 202Prostatic Neoplasms 118Polycystic Ovary Syndrome 114Colorectal Neoplasms 103Carcinoma, Hepatocellular 103Carcinoma, Non-Small-Cell Lung 88Lung Neoplasms 70Stomach Neoplasms 62Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Pain 59Neoplasm Metastasis 54Multiple Myeloma 52Pancreatic Neoplasms 46Keratosis, Actinic 46Head and Neck Neoplasms 43Pain, Postoperative 42Leukemia, Myeloid, Acute 40Leiomyoma 39Recurrence 38Liver Neoplasms 38Colonic Neoplasms 37Uterine Cervical Neoplasms 35Lymphoma 35Brain Neoplasms 34Infertility 33Papillomavirus Infections 32Ovarian Neoplasms 31Lymphoma, Follicular 31Lymphoma, Non-Hodgkin 30

Interventions

Prednisone 2enzalutamide 1cabazitaxel 1Prednisolone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Prostate Cancer Metastatic × Clear all
NCT02485691 2022-05-27

CARD

Sanofi

Phase 4 Completed
255 enrolled 21 charts
Genitourinary

Prostate Cancer Metastatic

NCT02074137 2016-06-02

Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer

Sanofi

Phase 4 Completed
10 enrolled
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡